Mesoblast Limited MESO announced that it has partnered with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to develop a pivotal phase III study of MESO’s lead product candidate, ...
Mesoblast Limited's Remestemcel-L has been approved for treating acute graft-versus-host disease, driving recent share price momentum and a potential market cap of $2 billion. The company is preparing ...
The FDA has rejected Mesoblast's cell therapy candidate for pediatric acute graft versus host disease, causing the stock to decline. Mesoblast is an old company located in Australia, which may impact ...
Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGVHD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback